Boadilla del Monte, Spain Clinical Trials

A listing of Boadilla del Monte, Spain clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 49 clinical trials
featured
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma who have received at least 3 but not more than 5 prior lines of multiple myeloma therapy. …

refractory multiple myeloma
daratumumab
FUNDACION JIMENEZ DIAZ UNIVERSITY HOSPITAL
 (8.2 away) Contact site
  • 71 views
  • 28 May, 2020
  • +27 other locations
featured
Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin’s Lymphoma

This is a multi-center Phase 1/2 open label trial of intratumoral G100 in patients with low grade NHL. Patients with NHL will be enrolled and receive G100 to an accessable tumor mass. Clinical response will be evaluated in the injected lesion and systemic (abscopal) responses will be evaluated in distal …

non-hodgkin's lymphoma
lymphomas
lymphoma
Hospital Puerta de Hierro-Majadahonda
 (4.7 away) Contact site
  • 73 views
  • 22 Dec, 2020
  • +30 other locations
Study to Assess Safety Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

The primary objective of this study is to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the …

START Madrid-Fundaci n Jim nez D az
 (8.2 away) Contact site
  • 28 views
  • 07 May, 2021
  • +27 other locations
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the …

afatinib
HER2
egfr t790m
epidermal growth factor receptor
growth factor
Hospital Universitario Puerta de Hierro - Majadahonda
 (4.7 away) Contact site
  • 0 views
  • 31 May, 2021
  • +97 other locations
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

Open-label, dose-confirmation and cohort expansion, multicentre, Phase Ib/II study to assess the anti-tumour activity and safety of MEN1611 in combination with cetuximab for the treatment of patients with PIK3CA mutated metastatic colorectal cancer.

PIK3CA
adenocarcinoma
oxaliplatin
measurable disease
irinotecan
Fundacion Jimenez Diaz
 (9.7 away) Contact site
  • 2 views
  • 27 Jan, 2021
  • +38 other locations
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.

This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participant ramp-up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory haematological malignancies.

Research Site
 (9.7 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +24 other locations
Study of Peposertib in Combination With Capecitabine and Radiotherapy in Rectal Cancer

The main purpose of the study is to define maximum tolerated dose (MTD), recommended Phase II dose (RP2D) of Peposertib in combination with capecitabine and radiotherapy (RT) in Phase Ib and to evaluate the efficacy of Peposertib in terms of Pathological Clinical Response (pCR)/Clinical Complete Response (cCR) when administered in …

Hospital Universitario 12 de Octubre - Servicio de Oncologia
 (9.7 away) Contact site
  • 2 views
  • 31 Jan, 2021
  • +14 other locations
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3 (VEGFR1-3), RET, AXL, FLT3 and KIT. Cabozantinib has been approved by the FDA for clinical treatment of progressive, metastatic medullary thyroid cancer. Recently published trials have …

bladder cancer
serum pregnancy test
growth factor
transitional cell carcinoma
kinase inhibitor
Hospital 12 de Octubre
 (9.7 away) Contact site
  • 46 views
  • 26 Jan, 2021
  • +11 other locations
INCB001158 Combined With Subcutaneous (SC) Daratumumab Compared to Daratumumab SC in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.

Fundacion Jimenez Diaz University Hospital
 (8.2 away) Contact site
  • 20 views
  • 03 Feb, 2021
  • +44 other locations
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in subjects with metastatic pancreatic cancer.

cancer
metastatic pancreatic cancer
chemotherapy regimen
leucovorin
adenocarcinoma
Research Site
 (8.2 away) Contact site
  • 63 views
  • 16 Jun, 2021
  • +26 other locations